LEXICON PHARMACEUTICALS, INC. — Director's Dealing 2013

Feb 4, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LEXICON PHARMACEUTICALS, INC./DE (LXRX)
CIK: 0001062822
Period of Report: 2013-01-31

Reporting Person: SANDS ARTHUR T (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-01-31	Common Stock	M	73700	—	Acquired	911088	Direct
2013-01-31	Common Stock	F	21434	$2.11	Disposed	889654	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-01-31	Restricted Stock Units (Phantom Stock)	$	M	73700	Disposed		Common Stock (73700)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	817500	Indirect
Common Stock	60000	Indirect

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.

F3: Restricted stock units vest with respect to 100% of the shares subject to the restricted stock unit upon the dosing of the first patient in a pivotal human clinical trial in any country, the results of which could be used to establish safety and efficacy of a pharmaceutical product discovered or developed by the Company (whether or not licensed by the Company to a third party) as a basis for a New Drug Application with the U.S. Food and Drug Administration or that would otherwise satisfy the requirements of 21 CFR 321.21(c) or its foreign equivalent.